p53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression?

Cancer

Volumn 85, Issue 11, 1999, Pages 2455-2459

  Cheng, Liang ^a,d   Leibovich, Bradley C ^b   Bergstralh, Erik J ^c   Scherer, Beth G ^c   Pacelli, Anna ^c   Ramnani, Dharamdas M ^c   Zincke, Horst ^b   Bostwick, David G ^b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF UROLOGY   (United States)

^c MAYO CLINIC   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Metastases; Progression; Prostate; Protein p53; Survival

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR VOLUME;

EID: 0033151791     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2455::AID-CNCR22>3.0.CO;2-C     Document Type: Article

References (23)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
3. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
5. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-73.
6. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, et al. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996;56:3814-22.
7. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994;151:1276-80.
8. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147:92-101.
9. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89(2):158-65.
10. Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159-66.
11. Bauer JJ, Sesterhen IA, Mostofi KF, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995;1: 1295-1300.
12. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997;158:131-7.
13. Cheng L, Bergstralh EH, Cheville JC, Slezak J, Corica FA, Zincke H, et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998;22:1491-500.
14. Bostwick DG. Neoplasms of the prostate. In: Bostwick DG, Eble JN, editors. Urologic surgical pathology. 1st edition. St. Louis: Mosby, 1997:343-422.
15. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998;82(11):2262-9.
16. Hughes JH, Cohen MB, Robinson RA. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma. Mod Pathol 1995;8(5):462-6.
17. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69.
18. Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y, Kawabe K. Combined analysis with Bc1-2 and P53 immuno-staining predicts poorer prognosis in prostatic carcinoma. J Urol 1997;158:2278-83.
19. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998;82(1): 168-75.
20. Kuczyk MA, Serth J, Bokemeyer C, Machtens S, Minssen A, Bathke W, et al. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 1998;34:679-86.
21. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 1998;159:1437-43.
22. Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 1996;47(3):366-9.
23. Masuda M, Takano Y, Iki M, Asakura T, Hashiba T, Noguchi S, et al. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: a retrospective immunohistochemical analysis. Pathol Int 1998;48:41-6.